SER
Serina Therapeutics, Inc.
Biotechnology
Market Cap$20M
5Y Perf.-95.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SER vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
SER vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SER | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $20M | $85M |
| Revenue (TTM) | $116K | $242K |
| Net Income (TTM) | $-19M | $-38M |
| Gross Margin | 56.9% | 59.5% |
| Operating Margin | -201.4% | -63.0% |
| Total Debt | $268K | $631K |
| Cash & Equiv. | $4M | $8M |
SER vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SER
NRXP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Serina Therapeutics… (SER) | 100 | 4.3 | -95.7% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SER vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NRXP leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Serina Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SER
Serina Therapeutics, Inc.
The Income Pick
SER is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.24
- Lower volatility, beta 1.24, Low D/E 52.8%, current ratio 2.40x
- Beta 1.24, current ratio 2.40x
Best for: income & stability and sleep-well-at-night
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 43.9%
- -96.8% 10Y total return vs SER's -98.1%
- 101.1% revenue growth vs SER's -98.2%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs SER's -98.2% |
| Quality / Margins | NRXP | -157.3% margin vs SER's -160.2% |
| Stability / Safety | SER | Beta 1.24 vs NRXP's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NRXP | +55.3% vs SER's -68.5% |
| Efficiency (ROA) | SER | -213.6% ROA vs NRXP's -489.9% |
SER vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
SER vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNRXPLAGGINGSER
SERSerina Therapeutics, …
0leads
NRXPNRx Pharmaceuticals, …
4leads
6 Total Categories
CATEGORYLEADERvs SERMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NRXP5/5
Valuation MetricsMultiples, price ratios, and targets
NRXP2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NRXP3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
NRXP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NRXP leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NRXP is the larger business by revenue, generating $242,000 annually — 2.1x SER's $116,000. Profitability is closely matched — net margins range from -157.3% (NRXP) to -160.2% (SER).
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $116,000 | $242,000 |
| EBITDAEarnings before interest/tax | -$23M | -$31M |
| Net IncomeAfter-tax profit | -$19M | -$38M |
| Free Cash FlowCash after capex | -$17M | -$12M |
| Gross MarginGross profit ÷ Revenue | +56.9% | +59.5% |
| Operating MarginEBIT ÷ Revenue | -201.4% | -63.0% |
| Net MarginNet income ÷ Revenue | -160.2% | -157.3% |
| FCF MarginFCF ÷ Revenue | -142.5% | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -4.4% | -80.0% |
NRXP leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
NRXP leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $20M | $85M |
| Enterprise ValueMkt cap + debt − cash | $16M | $78M |
| Trailing P/EPrice ÷ TTM EPS | -1.20x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 348.60x | 69.15x |
| Price / BookPrice ÷ Book value/share | 26.22x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
NRXP leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NRXP leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs SER's 2/9, reflecting solid financial health.
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -14.0% | — |
| ROA (TTM)Return on assets | -2.1% | -4.9% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -2.9% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.53x | — |
| Net DebtTotal debt minus cash | -$3M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $8M |
| Total DebtShort + long-term debt | $268,000 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | -581.22x | -24.18x |
NRXP leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
NRXP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SER five years ago would be worth $387 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, NRXP leads with a +55.3% total return vs SER's -68.5%. The 3-year compound annual growth rate (CAGR) favors NRXP at -21.0% vs SER's -55.6% — a key indicator of consistent wealth creation.
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | -12.9% | +16.8% |
| 1-Year ReturnPast 12 months | -68.5% | +55.3% |
| 3-Year ReturnCumulative with dividends | -91.3% | -50.6% |
| 5-Year ReturnCumulative with dividends | -96.1% | -99.1% |
| 10-Year ReturnCumulative with dividends | -98.1% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -55.6% | -21.0% |
NRXP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SER and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
SER is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than NRXP's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs SER's 22.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 1.89x |
| 52-Week HighHighest price in past year | $7.92 | $3.84 |
| 52-Week LowLowest price in past year | $1.22 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +22.9% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 45.1 | 64.7 |
| Avg Volume (50D)Average daily shares traded | 3.8M | 913K |
Evenly matched — SER and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SERSerina Therapeuti… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NRXP leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallNRx Pharmaceuticals, Inc. (NRXP)Leads 4 of 6 categories
Loading custom metrics...
SER vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SER or NRXP?
Over the past 5 years, Serina Therapeutics, Inc.
(SER) delivered a total return of -96. 1%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: NRXP returned -96. 8% versus SER's -98. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SER or NRXP?
By beta (market sensitivity over 5 years), Serina Therapeutics, Inc.
(SER) is the lower-risk stock at 1. 14β versus NRx Pharmaceuticals, Inc. 's 1. 89β — meaning NRXP is approximately 66% more volatile than SER relative to the S&P 500.
03Which is growing faster — SER or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to -339. 7% for Serina Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SER or NRXP?
NRx Pharmaceuticals, Inc.
(NRXP) is the more profitable company, earning -23. 4% net margin versus -198. 9% for Serina Therapeutics, Inc. — meaning it keeps -23. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRXP leads at -1324. 4% versus -304. 4% for SER. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SER or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SER or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Serina Therapeutics, Inc.
(SER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SER: -98. 2%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SER and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.